NASDAQ:NVCT Nuvectis Pharma Q3 2024 Earnings Report $22.00 +0.62 (+2.90%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$22.15 +0.15 (+0.66%) As of 09/18/2026 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Nuvectis Pharma EPS ResultsActual EPS-$0.24Consensus EPS -$0.25Beat/MissBeat by +$0.01One Year Ago EPS-$0.37Nuvectis Pharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ANuvectis Pharma Announcement DetailsQuarterQ3 2024Date11/5/2024TimeAfter Market ClosesConference Call DateTuesday, November 5, 2024Conference Call Time7:00AM ETUpcoming EarningsNuvectis Pharma's Q3 2026 earnings is estimated for Tuesday, November 3, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, November 4, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Nuvectis Pharma Earnings HeadlinesNuvectis Pharma: Haisco Licensing Deal Revitalises Biotech - But No Rush To Invest TodaySeptember 18 at 8:31 AM | seekingalpha.comNuvectis Pharma, Inc. (NASDAQ:NVCT) Receives Consensus Rating of "Moderate Buy" from BrokeragesSeptember 9, 2026 | americanbankingnews.comMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on September 25. Altucher is hosting a free masterclass revealing what he says is locked inside a sealed briefcase detailing Musk's plans. Attendees who join early can also access a $1,000 bonus offer included with the presentation. | Paradigm Press (Ad)Some of the Top Biotech Funds Just Bought Into This Under-the-Radar Biotech (NASDAQ: NVCT)September 3, 2026 | markets.businessinsider.comNuvectis Pharma To Participate in Upcoming Investor ConferencesSeptember 3, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Nuvectis Pharma (NVCT) and EyePoint Pharmaceuticals (EYPT)August 9, 2026 | theglobeandmail.comSee More Nuvectis Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Nuvectis Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nuvectis Pharma and other key companies, straight to your email. Email Address About Nuvectis PharmaNuvectis Pharma (NASDAQ:NVCT) is a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer and other serious diseases with limited therapeutic options. The company’s research and development efforts are centered on small-molecule medicines designed to target biological pathways involved in tumor growth and treatment resistance. Nuvectis’ lead programs include NXP800, an investigational inhibitor of the heat shock factor 1 pathway being evaluated for potential use in selected solid tumors, and NXP900, an investigational inhibitor of the SRC and YES1 protein kinases. These programs are being advanced through clinical development to assess their safety, tolerability and potential efficacy in cancer patients. The company was established in the early 2020s and became publicly traded on the Nasdaq exchange in 2022. Nuvectis Pharma is headquartered in Fort Lee, New Jersey, and is led by President and Chief Executive Officer Ron Bentsur. Its activities are primarily focused on drug development and clinical research, with programs intended for potential use in oncology markets in the United States and other regions.View Nuvectis Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles J.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. HousingLennar's Q3 Miss Hides a Stronger Operating Story Beneath the Housing SlumpAeluma’s Selloff Could Be Setting Up Its Next Big MoveBraze Beat Expectations—Now 2 SaaS Peers Are in FocusPriced for a Pullback or More Gains? These 3 Stocks Are Testing the LimitsCoreWeave’s Vera Rubin Lead Comes Down to Speed, Power, and Scale Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
